Table 1.

Composition and Characterization of the prepared RSV-loaded Silica Nanoparticles.

Formulation code	⁎⁎, ⁎, ⁎⁎Composition					Characterization
	⁎⁎Hydroalcoholic solution (v/v)		Nitrogen source (%w/v)	Silica source (%v/v)	Drug (%w/v)	PS	PDI	ZP	%DC
	Aqueous phase	Alcoholic phase	Ch. HCl	TEOS	RSV
RSNP1	1	1	0.1	10	0.2	342.90$\pm$34.60	0.59$\pm$0.07	11.70$\pm$0.10	94.91$\pm$1.29
RSNP2	1	1	0.1	20	0.2	221.00$\pm$7.30	0.39$\pm$0.02	12.90$\pm$2.80	100.22$\pm$0.67
RSNP3	2	1	0.1	10	0.2	496.25$\pm$1.85	0.63$\pm$0.15	9.97$\pm$2.23	89.82$\pm$0.22
RSNP4	2	1	0.1	20	0.2	362.35$\pm$54.05	0.47$\pm$0.05	10.85$\pm$0.75	99.16$\pm$0.62
RSNP5	3	1	0.1	10	0.2	1707.50$\pm$111.50	0.55$\pm$0.26	7.41$\pm$1.98	85.35$\pm$1.68
RSNP6	3	1	0.1	20	0.2	1374.50$\pm$72.50	0.56$\pm$0.33	9.65$\pm$3.06	91.67$\pm$2.18

Abbreviations: RSNP, Rosuvastatin entrapped silica nanoparticles; TEOS, Tetraethyl orthosilicate; RSV, Rosuvastatin; PS, Particle size; PDI, Polydispersity index; ZP, Zeta potential; %DC, % drug content.

^⁎Chitosan hydrochloride was dissolved in water (aqueous phase) while RSV was dissolved in propylene glycol (alcoholic phase). Following, the alcoholic solution was added to aqueous solution on stirring. TEOS was added dropwise to the hydroalcoholic solution.

^⁎All concentrations were relevant to the final volume.

^⁎⁎Aqueous and alcoholic phases were mixed as volume ratios.